COVID19

Ultomiris to Be Evaluated for Severe COVID-19 in Phase 3 Trial

A phase 3 study evaluating Ultomiris (ravulizumab-cwvz; Alexion) in hospitalized patients with coronavirus disease 2019 (COVID-19) is expected to begin in May.  The Food and Drug Administration recently accepted Alexion’s investigational new drug (IND) application for Ultmoiris for severe COVID-19. Ravulizumab-cwvz works by inhibiting the C5 protein in the terminal complement cascade. Some preclinical data…